Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 400 participants.

Also called NCT04607122

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose prevention
Phase
Phase 3
Enrolled
  • 400 participants (enrolled count) (from the registry)
Sponsor
CMC Ambroise Paré (from the registry)
Registry
  • NCT NCT04607122
  • EudraCT 2019-004829-25
Main results
  • Low dose of landiolol does not prevent postoperative atrial fibrillation after cardiac surgery in non-Asian patients: a multicentre randomised study British journal of anaesthesia, 2026-01 DOI, PubMed 41203473

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04607122. Randomized; quadruple masking; primary purpose prevention. Start 2021-01-27 (actual); primary completion 2023-06-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Prevention of Atrial Fibrillation by Low-dose Landiolol Administration After Cardiac Surgery
Acronym
LANDIPROTEC
Condition
Cardiac Surgery
Intervention (Drug)
Landiolol
Intervention (Drug)
Saline
Lead sponsor
CMC Ambroise Paré (class: other)

Record details

Record id
cardio:ct-nct04607122
Content hash
2e0ea01f9b63f82d1b29c14563a7373c85f640ec852fa4c41d18c1df699b0c41